Barcelona snapshots

Prof. Christoph U. Correll

Christoph U. Correll psiquiatra Controversias Psiquiatría Barcelona
Hofstra University, EE.UU. & Charité-Universitätsmedizin Berlin, Alemania
Ponencia Previniendo la resistencia al tratamiento desde el comienzo
Fecha Viernes, 26 de Abril, 2019
Hora 9:00 a 9:45
Mesa redonda Resistencia al tratamiento en esquizofrenia

BIOGRAFÍA

Prof. Dr. med Christoph Correll is Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Furthermore, he is Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City. Since 1997, he has been working and conducting research in New York, USA.

Professor Correll’s research and clinical work focus on the identification, characterisation and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness. He further focuses on psychopharmacology, epidemiology, comparative effectiveness, the risk–benefit evaluation of psychotropic medications and the interface between psychiatry and medicine.

He has authored or co-authored over 500 journal articles, and in October 2018 his H-index in Web of Science was 67 (Google Scholar: 86). He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll has received over 40 national and international research awards and fellowships for his work.

Since 2014, the year of inception of this metric, he has been listed every year by Thomson Reuters/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry” (https://clarivate.com/hcr/).

Additionally, he holds the following rankings:
  1. Ranked number 1 among world’s experts on the topic of psychotropic drugs, out of 119,436 ranked scientists (10/2018) (http://expertscape.com/ex/psychotropic+drugs)
  2. Ranked number 1 among world’s experts on the topic of schizophrenia, out of 65,021 ranked scientists (10/2018) (http://expertscape.com/ex/schizophrenia)
  3. Ranked number 1 among world’s experts on the topic of antipsychotics, out of 51,439 ranked scientists (10/2018) (http://expertscape.com/ex/antipsychotic+agents)
  4. Ranked number 2 among world’s experts on the topic of weight gain, out of 56,113 ranked scientists (10/2018) (http://expertscape.com/ex/weight+gain)
  5. Ranked number 6 among world’s experts on the topic of clozapine, out of 8,668 ranked scientists (10/2018) (http://expertscape.com/ex/clozapine)

RESUMEN

REFERENCIAS